Welcome to our dedicated page for IRWIN NATURALS SUB VTS news (Ticker: IWINF), a resource for investors and traders seeking the latest updates and insights on IRWIN NATURALS SUB VTS stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect IRWIN NATURALS SUB VTS's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of IRWIN NATURALS SUB VTS's position in the market.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Irwin Naturals Inc. (CSE: IWIN) (OTC: IWINF) has announced the national launch of its new CBD 25mg Softgels in Canada via the Starseed Medicinal Medical Group. This product marks the first release in a planned lineup of five cannabis products, including various CBD and THC formulations. The company aims to leverage its strong brand, recognized in 80% of American households, to penetrate the cannabis market further, targeting a wide range of consumer needs. Founded in 1994, Irwin Naturals operates profitably and seeks to expand into cannabis and psychedelics, with ambitions to establish itself as a household name in all 38 legal cannabis states.
Irwin Naturals Inc. has completed the acquisition of Keta Media, LLC, effective March 17, 2023, enhancing its presence in the ketamine therapy market. This strategic move aims to bolster the performance of Irwin's Emergence clinics and is expected to positively influence the company's annualized EBITDA. The acquisition allows Irwin to leverage Ketamine Media's marketing expertise to improve clinic utilization rates and support future expansion. The deal showcases Irwin's commitment to becoming a leading network of psychedelic mental health clinics.
Irwin Naturals Inc. (CSE: IWIN, OTC: IWINF) announced the acquisition of Keta Media, LLC, effective March 17, 2023. This strategic move aims to enhance the company's presence in the growing ketamine therapy market. The acquisition is expected to positively impact the company's annualized EBITDA and supports its ambition to create the largest network of psychedelic mental health clinics. Founder Klee Irwin expressed optimism about the collaboration leading to innovative marketing solutions, while Keta Media's CEO, Chris Walden, emphasized the growth potential for their advisory services. The total consideration includes cash and debt assumption.